Status:

COMPLETED

To Evaluate the Health Effect of Particular Fatty Acids Profiles From Eggs

Lead Sponsor:

Université Catholique de Louvain

Conditions:

Abdominal Obesity

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

In a previous study, 24 volunteers consumed two conventional eggs or two eggs naturally enriched with omega 3, 5 and 7 every day for 3 months. It was shown that these eggs were well tolerated and that...

Eligibility Criteria

Inclusion

  • Woman or man, aged of 18 to 75 years;
  • Abdominal obesity: waist circumference for men \> 94cm and \> 80cm for women;
  • Body mass index ≥ 25kg/m2 and ≤30kg/m2;
  • For women: use of effective contraception;
  • Provision of signed and dated informed consent form;
  • Stated willingness to comply with all study procedures and availability for the duration of the study;
  • French speaker.

Exclusion

  • Uncontrolled systolic blood pressure \> 160/100 mmHg;
  • For premenopausal women: pregnant women or women planning to get pregnant within 3 months or lactating women;
  • For menopausal women: less than 6 months of menopause;
  • For Perimenopausal women: presenting symptoms;
  • Type II diabetes (controlled or uncontrolled), Type I diabetes;
  • Medical history or actual cardiovascular disease (myocardial infarction, angina, transient ischemic attack, lower limb arteriopathy);
  • Medical history or actual severe psychiatric, hepatic, pancreatic, kidney, pulmonary or gastrointestinal problem
  • Thyroid disorder;
  • Cancer \< 3 years before the screening visit;
  • Smokers or who have stopped smoking within the last 6 months before the screening visit;
  • Subject presenting allergy or food intolerance to eggs;
  • Subjects who are not able to understand and follow study procedures;
  • Drug addiction problem (regular consumption);
  • Recent change of body weight \> 7% (\< 2 months before the inclusion);
  • Within 1 month before the screening visit, change in the chronic (\> 7 days in a row) intake or dosage of drug(s) or product(s) modifying the glucose and/or lipid metabolism;
  • Current or recent (\< 2 months before the screening visit) intake of dietary supplements rich in n-3 polyunsaturated fatty acid (including tablets, pills, capsules, enriched-oils);
  • Vegan diet;
  • Consumption of fish \> 3 times per week;
  • Women who drink more than 2 glasses of alcohol per day (\> 20 g of alcohol per day or \> 140g/week) or men who drink more than 3 glasses of alcohol per day (\> 30 g of alcohol per day or more than 210g/week);
  • LDL \> 159 mg/dl or Total cholesterol \> 239 mg/dl;
  • Subjects having participated to another clinical trial \< 1 month before the screening test visit.

Key Trial Info

Start Date :

October 22 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 11 2021

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT05413954

Start Date

October 22 2020

End Date

June 11 2021

Last Update

June 10 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UCLouvain - CICN

Louvain-la-Neuve, Belgium, 1348